These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17611409)

  • 21. β-Catenin is required for Ron receptor-induced mammary tumorigenesis.
    Wagh PK; Gray JK; Zinser GM; Vasiliauskas J; James L; Monga SP; Waltz SE
    Oncogene; 2011 Aug; 30(34):3694-704. PubMed ID: 21423209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines.
    Zhou DH; Li C; Yang LN
    Cancer Cell Int; 2015; 15(1):9. PubMed ID: 25685065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.
    Eckerich C; Schulte A; Martens T; Zapf S; Westphal M; Lamszus K
    J Neurochem; 2009 May; 109(4):969-80. PubMed ID: 19519771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
    Peace BE; Hughes MJ; Degen SJ; Waltz SE
    Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
    Wang MH; Yao HP; Zhou YQ
    Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
    Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
    Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
    Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration.
    Xiao ZQ; Chen YQ; Wang MH
    Biochem Biophys Res Commun; 2000 Jan; 267(2):669-75. PubMed ID: 10631120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.
    Angeloni D; Danilkovitch-Miagkova A; Miagkov A; Leonard EJ; Lerman MI
    J Biol Chem; 2004 Jan; 279(5):3726-32. PubMed ID: 14597639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
    Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
    J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.
    Collesi C; Santoro MM; Gaudino G; Comoglio PM
    Mol Cell Biol; 1996 Oct; 16(10):5518-26. PubMed ID: 8816464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
    Kim N; Cho SB; Park YL; Park SY; Myung E; Kim SH; Yu HM; Son YA; Myung DS; Lee WS; Joo YE
    Oncol Rep; 2016 Jun; 35(6):3331-40. PubMed ID: 27035413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The C terminus of RON tyrosine kinase plays an autoinhibitory role.
    Yokoyama N; Ischenko I; Hayman MJ; Miller WT
    J Biol Chem; 2005 Mar; 280(10):8893-900. PubMed ID: 15632155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nerigoside suppresses colorectal cancer cell growth and metastatic potential through inhibition of ERK/GSK3β/β-catenin signaling pathway.
    Wen SY; Chen YY; Deng CM; Zhang CQ; Jiang MM
    Phytomedicine; 2019 Apr; 57():352-363. PubMed ID: 30831484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.
    Chung CY; Park YL; Song YA; Myung E; Kim KY; Lee GH; Ki HS; Park KJ; Cho SB; Lee WS; Jung YD; Kim KK; Joo YE
    Dig Dis Sci; 2012 Feb; 57(2):371-80. PubMed ID: 21901254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase.
    Wang D; Shen Q; Chen YQ; Wang MH
    Oncogene; 2004 Mar; 23(9):1668-80. PubMed ID: 15001985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-talk between the proto-oncogenes Met and Ron.
    Follenzi A; Bakovic S; Gual P; Stella MC; Longati P; Comoglio PM
    Oncogene; 2000 Jun; 19(27):3041-9. PubMed ID: 10871856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.